TrialBMC medicine2026

Adjuvant tislelizumab, lenvatinib, and capecitabine for resected biliary tract cancer: a prospective phase II trial.

Yun Feng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.